Exact Sciences (EXAS) Stock: Buy, Sell, or Hold?
$104.91
+0.99 (+0.95%)
â˛
5d:
+1.29%
30d:
+1.57%
90d:
+3.15%
Open in Live Scanner
70/30 Portfolio Builder
Earnings: May 07, 2026
0d
Protect EXAS Gains
Updated Mar 20, 12:00 AM ET
QUANTITATIVE VERDICT
WAIT
LOW Confidence (74%)
Quality Score
52/100
Position
FAIR
Forward P/E & Valuation
55.8x
CHEAP
vs 79.4x historical avg
Wall Street Target
$105.81
+0.9% upside
Options IV & Volume
UNKNOWN Vol
UNKNOWN volume confirmation
Support / Resistance
$103.22 / $104.98
Trend: Strong Downtrend
Executive Thesis & Bottom Line
Forward Earnings Fair Value & Price Prediction →
âšī¸ NEUTRAL: EXAS is fairly priced but lacks strong directional signals. At -11.1% expected growth, valuation appears cheap. Wait for clearer setup or better entry on dips.
Get Alerted When EXAS Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$91.53
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$56.83
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 25.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: EXAS is currently trading at $104.91, which is considered fair based on recent price action. From a valuation perspective, the stock is trading at a discount (Forward PE: 55.8) compared to its historical average (79.4). Remarkably, the market is currently pricing in an annual earnings decline of 11.1% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, EXAS is in a strong downtrend. The price is currently testing key support at $103.22. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: EXAS scores 60/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, EXAS is in a strong downtrend. The price is currently testing key support at $103.22. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: EXAS scores 60/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
FAIR
Company Quality Score
52/100
(HOLD)
Volume Confirmation
UNKNOWN
Confidence Score
73.8%
Trading Range & Key Levels
Support Level
$103.22
Resistance Level
$104.98
Current Trend
Strong Downtrend
Technical data as of
Mar 20, 2026
Protect Your Profits
EXAS is technically overbought (RSI 76). Consider hedging now to protect against a potential pullback while keeping your upside.
View Profit Protection PlanQuantitative Signal Breakdown
- NEUTRAL: Price in fair range
- BULLISH: Strong technical setup (60/100)
- NEUTRAL: Near Wall St target ($105.81)
- WARNING: Composite score 52/100 in the bottom quintile â this cohort historically lags the market
Fundamental Context
Forward P/E (Next Year Est.)
55.80
Wall Street Target
$105.81
(+0.9%)
Revenue Growth (YoY)
23.1%
Profit Margin
-6.4%
Valuation Discount vs History
-11.1% cheaper
PE vs Historical
55.8 vs 79.4
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-11.1%
(market-implied from PE analysis)
1-Year Target
$94.42
(-10%)
2-Year Target
$84.98
(-19%)
3-Year Target
$76.48
(-27%)
3-Yr Target (if PE normalizes)
(PE: 56â79)
$108.82
(+4%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 55.8, Growth: 65.6%)
$354.07
(+238%)
Base:
(SPY PE: 22.4, Growth: 65.6%)
$142.00
(+35%)
Bear:
(PE: 19.0, Growth: 65.6%)
$120.70
(+15%)
đĄ
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 55.8 to 79.4
Stabilization Target:
$149.27
(+42.3%)
PE Expansion Potential:
+42.3%
Share EXAS Analysis
Share this live EXAS analysis (with rich preview card) to Reddit, StockTwits, X, or embed the chart on your blog.
bloggers & journalists: you are free to use our charts with attribution.Reddit & Retail Trader Sentiment (EXAS)
Bullish
2 Retail Mentions
Reddit / WSB Comments
1
Bearish
StockTwits Volume
1 msgs
24h retail stream
Last Tracked
Jun 7, 2026
Daily AI digest
AI Retail Discussion Summary:
Abbott is expected to close the acquisition of Exact Sciences on March 23, 2026, gaining entry into the fast-growing cancer screening and diagnostics segments.
Key Retail Themes:
Abbott's expansion into cancer screening and diagnostics
Closing of the acquisition of Exact Sciences
Aggregated from r/wallstreetbets, r/stocks & StockTwits streams.
View All Trending Reddit & WSB Stocks →
Last updated: November 11, 2026 8:32 PM ET
Data refreshes hourly during market hours. Next update: 9:32 PM
Data refreshes hourly during market hours. Next update: 9:32 PM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is EXAS showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Diagnostics & Research Stocks
Top-rated stocks in Diagnostics & Research by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
GH
Guardant Health Inc |
STRONG BUY
26 analysts |
$201 | 51 HOLD |
|
NTRA
Natera Inc |
STRONG BUY
23 analysts |
$416 | 65 BUY |
|
TMO
Thermo Fisher ScientificâĻ |
STRONG BUY
27 analysts |
$752 | 47 HOLD |
|
DHR
Danaher Corporation |
STRONG BUY
24 analysts |
$260 | 51 HOLD |
|
IQV
IQVIA Holdings Inc |
STRONG BUY
20 analysts |
$312 | 57 HOLD |
Advanced EXAS Option Strategies
Professional options setups generated by AI based on today's EXAS price and gamma walls.
Explore More Analysis & Live Quant Tools
Part A: Deep-Dive EXAS Research Pages
